



VIJAYA[®]
DIAGNOSTIC
CENTRE

July 09, 2026

The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Thursday, July 09, 2026

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time.

We hereby inform you that, the Board of Directors of the Company at their meeting held today i.e., on **Thursday, July 09, 2026**, has inter-alia considered and approved the appointment of Mr. Narasimha Raju K.A. as Chief financial officer of the Company w.e.f. July 09, 2026.

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as **Annexure-A**.

The Board Meeting commenced at 17:30 hrs and concluded at 17:40 hrs.

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

Naga Vasudha Tadepalli
Company Secretary & Compliance Officer
M. No.: A23711

Encl.: as above



Annexure-A

Details as per Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026

Particulars	NARASIMHA RAJU K A
Reason for Change viz. appointment, reappointment , resignation, removal, death or otherwise	Appointment as Chief Financial Officer
Date of appointment/ reappointment /cessation (as applicable) and term of appointment /reappointment	July 09, 2026.
Brief Profile (in case of appointment)	<p>Mr. Narasimha Raju K A is a Chartered Accountant and an accomplished Chief Financial Officer with over 20 years of extensive experience in finance, accounting, corporate governance, and strategic leadership. He combines a strong foundation in Big Four audit, having worked with S R Batliboi & Co (an affiliate of Ernst & Young), with senior leadership experience across the healthcare, diagnostics, renewable energy, and real estate sectors.</p> <p>Mr. Narasimha Raju was also the CFO of our Company during March 15, 2021 to March 26, 2025. Throughout his career, he has successfully led several high-impact strategic initiatives, including initial public offerings (IPOs), Draft Red Herring Prospectus (DRHP), investor relations, mergers and acquisitions, group restructurings, and regulatory compliance for both listed companies and private equity-backed organizations. He is recognized for executing complex capital market transactions within challenging timelines, including the successful completion of our Company's IPO during the COVID-19 pandemic, while strengthening corporate governance frameworks in alignment with Board and Audit Committee expectations.</p> <p>His areas of expertise include investor relations and stakeholder management, mergers, acquisitions and demergers, private equity, financial reporting and consolidation under Ind AS and IFRS, Board and Audit Committee governance, tax structuring and cross-border</p>



	<p>transactions, budgeting, management information systems (MIS) and performance management, risk management and internal controls, as well as regulatory, secretarial, and statutory compliances.</p> <p>Prior to rejoining the Company now, Mr. Narasimha Raju served as the Chief Financial Officer of Yashoda Group of Hospitals.</p> <p>Mr. Narasimha Raju's rich professional experience, strong financial acumen, and proven leadership in corporate finance, governance, and strategic transactions is expected to further strengthen the Company's financial management, governance standards, and long-term strategic objectives.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018	Not Applicable